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Abstract 
Background: Dys-megakaryopoiesis is defined as ≥10 % of dysplastic megakaryocytes in bone marrow smears by 
the World Health Organization. However, concordance rates for dysplastic megakaryocytes between different observ-
ers is low and, consequently, evaluation of dysmegakaryopoiesis is also often discordant.
Results: We performed CD41 immune staining and proposed a systematic classification of dys-megakaryopoiesis 
on bone marrow films: (1) micro-megakaryocytes (<12 µm); (2) micro-megakaryocytes (12–40 µm) with 1 nucleus; (3) 
micro-megakaryocytes (12–40 µm) with 2 nuclei; (4) micro-megakaryocytes (12–40 um) with multiple (more than 2) 
nuclei; (5) dysplastic megakaryocytes (≥40 µm) with 1 nucleus; (6) dysplastic megakaryocytes (≥40 µm) with 2 nuclei; 
and (7) dysplastic megakaryocytes (≥40 µm) with multiple (more than 2) nuclei. Further, we evaluated the prognos-
tic impact of micro-megakaryocytes and dysplastic mono-nucleated megakaryocytes on MDS patients. The best 
discriminator cut-off point for each group was determined by the minimal P value approach. In multivariate analyses 
micro-megakaryocytes ≥25 % and dysplastic mono-nucleated megakaryocytes ≥30 % were independent adverse 
prognostic factors (hazard ratio [HR] = 1.58 [95 % confidence interval [CI], 1.11, 2.23]; P = 0.010 and 1.53 [1.09, 2.16]; 
P = 0.014).
Conclusions: Our data suggest integration of micro-megakaryocytes and dysplastic mono-nucleated megakaryo-
cytes improve predictive accuracy of the international prognostic scoring system-revised (IPSS-R) scoring system.
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Background
Myelodysplastic syndromes (MDS) are a heterogeneous 
group of bone marrow neoplasms with variable clinical 
courses and prognoses [1]. Distinguishing the different 
form of MDS is important for accurate diagnosis, pre-
dicting outcomes and directing therapy. Several variables 
are used to distinguish different forms of MDS including 
morphology, histology, blood and bone marrow cell 
counts, cytogenetics and molecular genetics. Despite 
recent advances, cytological features in blood films and 
bone marrow aspirates and histological findings in tre-
phine biopsies remain key elements for diagnosing MDS 
[2, 3]. Among the histological parameters of MDS, multi-
lineage dysplasia and percent bone marrow blasts are 
associated with unfavorable outcomes [4–7].
Megakaryocyte morphology is another important 
component in classifying MDS. The World Health 
Organization (WHO) 2008 classification defines dys-
megakaryopoiesis as micro-megakaryocytes, hypo-lobed, 
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or non-lobed nuclei in megakaryocytes of all sizes and 
multiple, widely-separated nuclei [8]. Although this 
definition of dys-megakaryopoiesis is potentially useful, 
there is no precise definition of micro-megakaryocytes 
in the WHO classification. Consequently it is not sur-
prising that there is low concordance amongst observers 
for micro-megakaryocytes in bone marrow samples from 
persons with MDS [4, 9–12].
Megakaryocytes express surface CD41/CD61 and/or 
CD42b and CD42a [13, 14]. The glycoprotein (Gp) IIb 
(CD41), which has been considered a specific marker 
for the megakaryocyte lineage [15], can be detected 
during megakaryocytic differentiation at a stage of a 
late megakaryocytic progenitor [16–18]. Consequently, 
using CD41 to identify megakaryocytes may be a better 
way to define dysplastic megakaryocytes than Wright-
Giemsa or May-Grünwald-Giemsa staining. We used 
CD41 immune staining to identify megakaryocytes and 
assess if they were dysplastic in bone marrow smears 
from persons with MDS. Further, we tried to describe the 
morphological features of megakaryocytic dysplasia by 
developing a systematic classification of megakaryocytic 
dysplasia and analyze the impact of our classification of 




The study was approved by the ethics committees of the 
institute of hematology, Chinese Academy Of Medical 
Sciences (CAMS) and Peking Union Medical College 
(PUMC) according to guidelines of the declaration of 
Helsinki. In this retrospective analysis, the study cohort 
included 422 consecutive new-diagnosed subjects that 
were seen at the Institute of Hematology and Blood 
Disease Hospital, Chinese Academy of Medical Sci-
ences from January, 2000 to April, 2014. 8 subsequently 
received a haematopoietic cell transplant, 14, decit-
abine, 45, other chemotherapy and the remainder cyclo-
sporine  or thalidomide and best supportive care. Cases 
were re-reviewed by two blinded pathologists (W Cui 
and W Cai) and classified using the 2008 WHO criteria 
[2]. Subjects with suspected therapy-related MDS were 
excluded as the clinical course was typically progressive 
and treatment with conventional therapy was usually 
associated with a poor prognosis [19]. Furthermore, there 
was no Down Syndrome patient in the cohort. Follow-up 
data were available for 370 subjects (88  %). Date of last 
follow-up was December 15, 2014 or date of last contact. 
Median follow-up was 22 months (range 1–180 months). 
Subjects with lower-risk MDS fall into the international 
prognostic scoring system-revised (IPSS-R) categories of 
very low-, low-, and intermediate-risk groups and those 
with higher-risk MDS into the high- and very high-risk 
groups [20].
Cytologic analysis
Bone marrow smears from diagnosis were reviewed using 
an avidin–biotin-complex method (ABC; CD41 immune 
staining) by the experts who were blinded for patients’ 
diagnoses, cytopenias and cytogenetic status in cytology. 
The preparation of bone marrow smear was a relatively 
uniform procedure. The marrow area on every smear was 
approximate to 1.5 ×  3.0  cm with proper and relatively 
uniform thickness. ≥30 megakaryocytes were evaluated 
and the frequency of morphologic abnormalities was 
recorded. The presence of nuclear hypolobation, single or 
multiple separate small round nuclei were considered as 
main characteristics of dys-megakaryocytopoiesis.
Statistical analyses
Statistical analyses were performed using SPSS 19.0 soft-
ware or SAS software. The best discriminator thresh-
old was detected using the minimal P value approach (a 
method aimed at minimizing the identification of rare 
classes of subjects) and considering survival (log-rank 
statistic) as the dependent variable [21, 22]. The func-
tional form of the covariate under study was also evalu-
ated using Martingale residual analysis [23].
Numerical variables were summarized by median and 
range. Categorical variables were described with count 
and relative frequency (%) of subjects in each category. 
Comparison of numerical variables between groups was 
carried out using a non-parametric approach (Mann–
Whitney test). Comparison of the distribution of categor-
ical variables in different groups was performed with χ2 
test (unordered categorical variable) or the non-paramet-
ric approach (ordinal categorical variable).
Median survival was estimated using the Kaplan–
Meier method and compared using the log-rank test. Cox 
proportional hazard regression model was used for mul-
tivariate analyses. P values were two-tailed and statistical 
significance was set as the level of P < 0.05.
Results
Subjects variables
Median age at diagnosis was 50 years (range 16–83 years). 
286 subjects (68 %) were male. Distribution of WHO sub-
types, IPSS-R cytogenetic category and IPSS-R classifica-
tion are indicated in Table 1.
Cyto‑morphologic evaluation of megakaryocyte dysplasia
Megakaryocyte dysplasia was detected in 374 subjects 
(89  %). Median frequency of dysplastic megakaryo-
cytes was 14 % (range 0–100 %). Patients without mega-
karyocytic dysplasia included RA (17  %), RARS (15  %), 
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RCMD (42  %), RAEB-1 (17  %), RAEB-2 (6  %), MDS-U 
(4  %). Dysplastic megakaryocytes were assigned to 7 
categories: (1) micro-megakaryocytes (<12  µm); (2) 
micro-megakaryocytes (12–40  µm) with 1 nucleus; (3) 
micro-megakaryocytes (12–40  µm) with 2 nuclei; (4) 
micro-megakaryocytes (12–40 um) with multiple (more 
than 2) nuclei; (5) dysplastic megakaryocytes (≥40  µm) 
with 1 nucleus; (6) dysplastic megakaryocytes (≥40 µm) 
with 2 nuclei; and (7) dysplastic megakaryocytes 
(≥40 µm) with multiple (more than 2) nuclei (Fig. 1). The 
most frequent dysplastic megakaryocytes were micro-
megakaryocytes (12–40  µm) with 1 nucleus and dys-
plastic megakaryocytes (≥40  µm) with 1 nucleus, with 
median frequency of 28 % (0–91 %) and 29 % (0–78 %), 
respectively. Distribution of each type is shown in Addi-
tional file 1: Figure S1.
To analyze the prognostic impact of dys-megakary-
opoiesis, we identified the cutoff point for the two prog-
nostic classes with the greatest differences according to 
the smallest P value for micro-megakaryocytes at 25  % 
as well as mono-nucleated dys-megakaryopoiesis at 
30  %. Subjects without megakaryocytic dysplasia were 
all grouped to micro-megakaryocytes <25 % and mono-
nucleated dys-megakaryopoiesis <30 %.
Association between subject variables and megakaryocyte 
dysplasia
Clinical and laboratory variables in subjects with micro-
megakaryocytes  <25 and ≥25  % are compared in Addi-
tional file  1: Table S1. A similar comparison between 
subjects with mono-nucleated dys-megakaryopoiesis <30 
and ≥30 % is outlined in Additional file 1: Table S2.
Increased micro-megakaryocytes and mono-nucleated 
dys-megakaryopoiesis were significantly associated with 
lower levels of platelet count (P  <  0.001 and P  <  0.001) 
and higher levels of bone marrow blasts (P  <  0.001 
and P  <  0.001). Distributions of WHO 2008 subtypes 
(P =  0.001 and P < 0.001), IPSS-R cytogenetic category 
(P  =  0.002 and P  =  0.001) and IPSS-R risk cohorts 
(P  <  0.001 and P  <  0.001) were also significantly differ-
ent. There was no significant difference in age, gender, 
hemoglobin concentration and blood neutrophil counts 
at diagnosis between the two groups. In addition, levels 
of micro-megakaryocytes and dysplastic mono-nucleated 
megakaryocytes were significantly associated with abnor-
mal karyotype (P = 0.026 and P = 0.014), complex karyo-
type (CK) (P =  0.034 and P =  0.022) and chromosome 
7 aberrations (P  =  0.004 and P  =  0.003), but not with 
monosomal karyotype (MK) or del(5q) (Additional file 1: 
Table S3).
Prognostic implications of megakaryocyte dysplasia
In univariate analyses, subjects with micro-megakary-
ocytes  ≥25  % had poorer survival (median, 19  months 
[95  % CI 14–23  months]) than those with micro-
megakaryocytes  <25  % (46  months [28–64  months], 
P  <  0.001; Fig.  2a). Similarly, patients with dysplastic 
mono-nucleated megakaryocytes  ≥30  % demonstrated 
poorer survival as compared to those with dysplastic 
mono-nucleated megakaryocytes  <30  % (18  months 
[14–23  months] vs. 49  months [31–68  months], 
P  <  0.001; Fig.  2b). Other significant predictors of sur-
vival in univariate analyses were male gender (P = 0.009), 
age  ≥60  years (P  <  0.001), hemoglobin concentra-
tion <80 g/L (P = 0.001), neutrophils <0.8 × 10E + 9/L 
(P = 0.001), platelets <50 × 10E + 9/L (P = 0.002), bone 
marrow blasts >10 % (P < 0.001), IPSS-R cytogenetic cat-
egory (P < 0.001) and IPSS-R score (P < 0.001).
We performed a multivariate Cox regression model 
including gender, age, micro-megakaryocytes and 
IPSS-R. Male gender (hazard ratio [HR] =  1.5; 95 % CI 
1.0–2.0; P = 0.029), age ≥60 years (HR = 1.5; [1.1–2.0]; 
P  =  0.016), micro-megakaryocytes  ≥25  % (HR  =  1.6 
[1.1–2.2]; P = 0.010) and IPSS-R score (P < 0.001) were 
significantly associated with survival (Table  2). In a 
similar analysis including gender, age, dysplastic mono-
nucleated megakaryocytes and IPSS-R, only male gender 
(HR =  1.5; 95  % CI 1.0–2.0; P =  0.028), age ≥60  years 
Table 1 Clinical variables (N = 422)
Subjects (n = 422)
Median age (range, years) 50 (16–83)
Male 286 (68 %)
WHO classification
 RA 22 (5 %)
 RN 2
 RT 3
 RARS 24 (6 %)
 RCMD 198 (47 %)
 RAEB-1 84 (20 %)
 RAEB-2 76 (18 %)
 MDS-U 8
 MDS with del(5q) only 5
IPSS-R cytogenetic category
 Very-good 6
 Good 208 (49 %)
 Intermediate 143 (34 %)
 Poor 23 (5 %)
 Very-poor 42 (10 %)
IPSS-R (%)
 Very-low 6
 Low 99 (23 %)
 Intermediate 135 (32 %)
 High 105 (25 %)
 Very-high 77 (18 %)
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(HR = 1.5; 95 % CI 1.1–2.0; P = 0.018), dysplastic mono-
nucleated megakaryocytes ≥30 % (HR = 1.533; [1.1–2.2]; 
P = 0.014) and IPSS-R (P < 0.001) remained in the final 
model (Table 3). 
Prognostic implications of megakaryocytic dysplasia 
in IPSS‑R lower‑risk subjects according to the IPSS‑R score
In the IPSS-R lower-risk subjects, those with micro-
megakaryocytes  ≥25  % had a poorer survival than 
patients with micro-megakaryocytes  <25  % (P  <  0.001; 
Fig.  3a). Similarly, there was a significant difference 
in survival between patients with mono-nucleated 
dys-megakaryopoiesis <30 and ≥30 % (P < 0.001; Fig. 3b). 
This association was not significant in subjects in the 
IPSS-R higher-risk cohort. Consequently, we performed 
stratified multivariate analyses to further evaluate prog-
nostic implications of megakaryocytic dysplasia in IPSS-R 
lower-risk subjects only. In the model of cell size including 
age, gender, IPSS-R and micro-megakaryocytes, only age, 
IPSS-R and micro-megakaryocytes were significantly cor-
related with survival (Table 4). In a similar analysis con-
sidering dysplastic mono-nucleated megakaryocytes, only 
age, IPSS-R and dysplastic mono-nucleated megakaryo-
cytes were significantly correlated with survival (Table 5).  
Fig. 1 Wright-Giemsa staining and CD41 immune staining of dysplastic megakaryocytes on bone marrow smears
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Discussion
In the WHO classification of myeloid neoplasms bone 
marrow dysplasia ≥10 % of the cells of a specific myeloid 
lineage is the cardinal diagnostic feature of the MDS. 
However, morphology is a subjective parameter under 
the routine staining conditions. For example, concord-
ance for dys-megakaryopoiesis amongst observers was 
less than concordance for dys-granulopoiesis and dys-
erythropoiesis [4]. Thus, specific immune staining may 
be a better way to evaluate megakaryocytes than routine 
histological methods [24].
Based on data from our study we propose a system-
atic classification of dys megakaryopoiesis on bone mar-
row films of persons with suspected MDS using CD41 
immune staining. A study has reviewed marrow smears 
of 26 RA and 28 RAEB patients, and micro-megakar-
yocytes were identified in 39.3 and 46.5  % cases under 
Wright-Giemsa staining, compared with 92.3 and 100 % 
under CD41 immune staining (χ2 test: P  <  0.005 and 
P = 0.01) (Wenyu Cai, unpublished data).
In our study, a larger number of dysplastic megakaryo-
cytes was significantly associated with decreased platelet 
Fig. 2 a Survival of 370 subjects with micro-megakaryocyte <25 or ≥25 %; b Survival of subjects with dysplastic mono-nucleated megakaryo-
cytes <30 or ≥30 %
Table 2 Multivariate Cox regression analysis with  respect 
to micro-megakaryocytes
* The reference 
HR 95 % CI P value
Gender 0.029
 Male 1.458 1.039–2.047
 Female* 1.0
Age (year) 0.016
 ≥60 1.485 1.078–2.047
 <60* 1.0
IPSS-R <0.001
 Very-low 0 0–2.31E133
 Low 0.106 0.062–0.180
 Intermediate 0.227 0.151–0.341
 High 0.597 0.410–0.869
 Very-high* 1.0
Micro-megakaryocytes (%) 0.010
 ≥25 1.575 1.113–2.230
 <25* 1.0 1.0
Table 3 Multivariate Cox regression analysis with  respect 
to dysplastic mono-nucleated megakaryocytes
* The reference 
HR 95 % CI P value
Gender 0.028
 Male 1.465 1.042–2.058
 Female* 1.0
Age (year) 0.018
 ≥60 1.474 1.068–2.034
 <60* 1.0 –
IPSS-R <0.001
 Very-low 0 0–5.24E132
 Low 0.108 0.063–0.185
 Intermediate 0.235 0.155–0.355
 High 0.607 0.416–0.885
 Very-high* 1.0
Mono-nucleated (%) 0.014
 ≥30 1.533 1.089–2.160
 <30* 1.0
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count, increased bone marrow blasts and increased IPSS-
R scores. Cytogenetic abnormalities are associated with 
characteristic dysplastic features, e.g. isolated del(5q) 
and hypo-lobed and un-lobed megakaryocyte nuclei 
and del(17p) with hypo-lobed neutrophil nuclei [25]. 
Data from our study also indicated parallel increases in 
micro-megakaryocytes and dysplastic mono-nucleated 
megakaryocytes and IPSS-R cytogenetic scores, as well as 
frequencies of abnormal karyotype, CK and chromosome 
7 aberrations. However, according to our study, there was 
no significant association of dysplastic megakaryocytes 
with del(5q). Hypolobulation is also commonly seen in all 
other subtypes besides MDS with del(5q) only. This unex-
pected result may be on account of the small proportion 
of del(5q) patients in our study cohort (5/422). A larger 
dataset is necessary for further research on this issue. 
Furthermore, we suspect that abnormalities in process 
of endo-reduplication may play a more important role 
than aberrant endomitosis in dysplastic megakaryocytes, 
for micro-megakaryocytes with 1 nucleus and dysplastic 
megakaryocytes (≥40 µm) with 1 nucleus were most fre-
quently seen in our study.
Studies reported a threshold of 10 % dysplastic granu-
locytes as well as 30–40  % dysplastic megakaryocytes 
as the best survival discriminator [4, 11, 26, 27]. We 
found a threshold of 25 % of micro-megakaryocytes and 
30  % of dysplastic mono-nucleated megakaryocytes as 
the best survival discriminators, which was independ-
ent of age, gender and IPSS-R risk score. We also found 
Fig. 3 a Survival of subjects with IPSS-R lower-risk with micro-megakaryocyte <25 or ≥25 %; b survival of subjects with dysplastic mono-nucleated 
megakaryocytes <30 or ≥30 %
Table 4 Multivariate analysis of  the survival of  IPSS-R 
lower-risk subjects with respect to micro-megakaryocytes
* The reference 
HR 95 % CI P value
Age (year) 0.024




 Very-low 0 0–6.17E272
 Low 0.478 0.280–0.816
 Intermediate* 1.0
Micro-megakaryocytes (%) <0.01
 ≥25 2.806 1.509–5.218
 <25* 1.0
Table 5 Multivariate analysis of  the survival of  IPSS-R 
lower-risk subjects with respect to dysplastic mono-nucle-
ated megakaryocytes
* The reference 
HR 95 % CI P value
Age (year) 0.03




 Very-low 0 0–1.07E266
 Low 0.463 0.272–0.789
 Intermediate* 1.0
Mono-nucleated (%) <0.01
 ≥30 2.672 1.410–5.064
 <30* 1.0
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micro-megakaryocytes and dysplastic mono-nucleated 
megakaryocytes were independently associated with 
survival in subjects with IPSS-R lower-risk MDS. Based 
on these data we suggest that adding these variables to 
the IPSS-R model could improve the predictive accu-
racy in untreated subjects and those with IPSS-R lower-
risk MDS. External validation of concordance between 
observers using our technique and dysplastic megakaryo-
cytes classification is needed.
Authors’ contributions
ZJX designed the research, was the principal investigator, and took primary 
responsibility for the paper; GF acquisition of data, analysis and interpreta-
tion of data, and drafting the article; WC, WC, GH acquisition of data; TJQ, 
YZ, LWF, HLZ, LJP, NBH, SQQ, BL and ZJX recruited the patients; ZJX, RPG, 
JMB, PLG wrote the typescript. All authors read and approved the final 
manuscript.
Author details
1 MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, 
Chinese Academy of Medical Sciences & Peking Union Medical College, 288 
Nanjing Road, Tianjin 300020, China. 2 State Key Laboratory of Experimental 
Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese 
Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. 
3 Hematology Research Center, Division of Experimental Medicine, Depart-
ment of Medicine, Imperial College London, London, UK. 4 Department 
of Pathology, Institute of Hematology and Blood Diseases Hospital, Chinese 
Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. 
5 Divisions of Experimental Hematology and Cancer Biology, Cincinnati Chil-
dren’s Hospital Medical Center, Cincinnati, OH, USA. 
Acknowledgements
Supported in part by National Natural Science Funds (No. 81470295, No. 
81470297, No. 81370611, No. 81530008), Program for Peking Union Scholars 
and Innovative Research Team and National Key Technology R&D Program 
(No. 2014BAI09B13). RPG acknowledges support from the NIHR Biomedical 
Research Centre funding scheme. We thanks Professor B. Bain (London, UK) for 
her very helpful suggestions.
Competing interests
RPG is a part-time employee of Celgene Corp. The authors declare that they 
have no competing interests.
Received: 4 April 2016   Accepted: 8 April 2016
References
 1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 
2009;361:1872–85.
 2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. 
The 2008 revision of the World Health Organization (WHO) classifica-
tion of myeloid neoplasms and acute leukemia: rationale and important 
changes. Blood. 2009;114:937–51.
Additional file
Additional file 1. Distribution of dysplastic megakaryocytes in subjects 
and variables of subjects with dysplastic megakaryocytes.
 3. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo 
C, et al. Diagnosis and treatment of primary myelodysplastic syndromes 
in adults: recommendations from the European LeukemiaNet. Blood. 
2013;122:2943–64.
 4. Matsuda A, Germing U, Jinnai I, Iwanaga M, Misumi M, Kuendgen A, 
et al. Improvement of criteria for refractory cytopenia with multiline-
age dysplasia according to the WHO classification based on prognostic 
significance of morphological features in patients with refractory anemia 
according to the FAB classification. Leukemia. 2007;21:678–86.
 5. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. Inter-
national scoring system for evaluating prognosis in myelodysplastic 
syndromes. Blood. 1997;89:2079–88.
 6. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, 
Invernizzi R, et al. Time-dependent prognostic scoring system for predict-
ing survival and leukemic evolution in myelodysplastic syndromes. J Clin 
Oncol. 2007;25:3503–10.
 7. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. 
Revised international prognostic scoring system for myelodysplastic 
syndromes. Blood. 2012;120:2454–65.
 8. Swerdllow S, Campo E, Harris NL. WHO classification of tumours of hae-
matopoietic and lymphoid tissues. France: IARC Press; 2008. p. 2008.
 9. Kuriyama K, Tomonaga M, Matsuo T, Ginnai I, Ichimaru M. Diagnostic 
significance of detecting pseudo-Pelger-Huet anomalies and micro-meg-
akaryocytes in myelodysplastic syndrome. Br J Haematol. 1986;63:665–9.
 10. Matsuda A, Jinnai I, Yagasaki F, Kusumoto S, Minamihisamatsu M, Honda 
S, et al. Refractory anemia with severe dysplasia: clinical significance of 
morphological features in refractory anemia. Leukemia. 1998;12:482–5.
 11. Della Porta MG, Travaglino E, Boveri E, Ponzoni M, Malcovati L, Papaem-
manuil E, et al. Minimal morphological criteria for defining bone marrow 
dysplasia: a basis for clinical implementation of WHO classification of 
myelodysplastic syndromes. Leukemia. 2015;29:66–75.
 12. Germing U, Strupp C, Giagounidis A, Haas R, Gattermann N, Starke C, 
et al. Evaluation of dysplasia through detailed cytomorphology in 3156 
patients from the Dusseldorf Registry on myelodysplastic syndromes. 
Leukemia Res. 2012;36:727–34.
 13. Abgrall JF, Berthou C, Sensebe L, Le Niger C, Escoffre M. Decreased in vitro 
megakaryocyte colony formation in chronic idiopathic thrombocyto-
penic purpura. Br J Haematol. 1993;85:803–4.
 14. Alimardani G, Guichard J, Fichelson S, Cramer EM. Pathogenic effects 
of anti-glycoprotein Ib antibodies on megakaryocytes and platelets. 
Thromb Haemost. 2002;88:1039–46.
 15. Vinci G, Tabilio A, Deschamps JF, Van Haeke D, Henri A, Guichard J, et al. 
Immunological study of in vitro maturation of human megakaryocytes. 
Br J Haematol. 1984;56:589–605.
 16. Rabellino EM, Levene RB, Leung LL, Nachman RL. Human megakaryo-
cytes. II. Expression of platelet proteins in early marrow megakaryocytes. J 
Exp Med. 1981;154:88–100.
 17. Kanz L, Mielke R, Fauser AA. Analysis of human hemopoietic progenitor 
cells for the expression of glycoprotein IIIa. Exp Hematol. 1988;16:741–7.
 18. Debili N, Issaad C, Masse JM, Guichard J, Katz A, Breton-Gorius J, et al. 
Expression of CD34 and platelet glycoproteins during human mega-
karyocytic differentiation. Blood. 1992;80:3022–35.
 19. Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. 
Semin Oncol. 2013;40:666–75.
 20. Sekeres MA, Gerds AT. Established and novel agents for myelodysplastic 
syndromes. Hematol Am Soc Hematol Educ Progr. 2014;2014:82–9.
 21. Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 
1992: 73–85.
 22. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using 
“optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer 
Inst. 1994;86:829–35.
 23. Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for 
survival models. Biometrika. 1990;77:147–60.
 24. Das R, Hayer J, Dey P, Garewal G. Comparative study of myelodys-
plastic syndromes and normal bone marrow biopsies with conven-
tional staining and immunocytochemistry. Anal Quant Cytol Histol. 
2005;27:152–6.
Page 8 of 8Feng et al. Exp Hematol Oncol  (2016) 5:12 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 25. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P, 
et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p 
deletion. An entity characterized by specific dysgranulopoiesis and a 
high incidence of P53 mutations. Leukemia. 1995;9:370–81.
 26. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the 
WHO proposals for a new classification of primary myelodysplastic 
syndromes: a retrospective analysis of 1600 patients. Leukemia Res. 
2000;24:983–92.
 27. Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S, 
et al. Difference in clinical features between Japanese and German 
patients with refractory anemia in myelodysplastic syndromes. Blood. 
2005;106:2633–40.
